Skip to Main content Skip to Navigation

A galactosidase-responsive doxorubicin-folate conjugate for selective targeting of acute myelogenous leukemia blasts

Abstract : Cytarabine combined with an anthracycline or an anthracenedione represents the usual intensive induction therapy for the treatment of AML. However, this protocol induces severe side effects and treatment-related mortality due to the lack of selectivity of these cytotoxic agents. In this paper, we present the study of the first galactosidase-responsive molecular "Trojan Horse" programmed for the delivery of doxorubicin exclusively inside AML blasts over-expressing the folate receptor (FR). This targeting system allows the selective killing of AML blasts without affecting normal endothelial, cardiac or hematologic cells from healthy donors suggesting that FDC could reduce adverse events usually recorded with anthracyclines.
Complete list of metadatas

Cited literature [40 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02444614
Contributor : Sylvain Fraineau <>
Submitted on : Saturday, January 18, 2020 - 11:19:47 AM
Last modification on : Monday, March 16, 2020 - 3:04:02 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Jonathan Clarhaut, Sylvain Fraineau, Joëlle Guilhot, Elodie Péraudeau, Isabelle Tranoy-Opalinski, et al.. A galactosidase-responsive doxorubicin-folate conjugate for selective targeting of acute myelogenous leukemia blasts. Leukemia Research, Elsevier, 2013, 37 (8), pp.948 - 955. ⟨10.1016/j.leukres.2013.04.026⟩. ⟨inserm-02444614⟩

Share

Metrics

Record views

54